Pexip tripled quarterly free cash flow. Its shares fell 7% on 5 November. RaySearch reported record sales. Its shares dropped more than 15% on 3 November. Two encouraging headlines, two painful days for shareholders.
These are the reports that make me want to look closer. Has the market spotted a problem the headline misses, or has a disappointing quarter changed the price more than the long-term opportunity? My latest Pexip and RaySearch reviews tackle that question from two very different angles.
Pexip brought the cash. Investors wanted more.
Free cash flow of USD 8.6m, up from USD 2.8m a year earlier, is a result worth noticing. Yet anyone looking only at the share-price reaction could have mistaken it for a bad quarter.
Inside Pexip, two stories are unfolding. Its secure video business is winning work with defence and court customers. The business connecting meeting rooms across platforms is having a harder time getting existing customers to spend more.
The challenge is deciding which story matters most over the next few years, and what the shares are worth if the stronger business keeps growing. A 7% fall changes the price. It does not answer that question.
Read my Pexip review for the investment case, updated valuation and verdict.
RaySearch’s sales record did not protect the shares
RaySearch’s reaction was even harsher. Record revenue sounds like the sort of news shareholders should welcome. The complication was what the company sold.
A larger share came from hardware, while the long-term attraction is the software that helps cancer clinics plan and deliver treatment. A bigger sales number is less exciting if it does not bring the earnings and cash investors expected.
My review asks whether the software opportunity still supports the investment case after that disappointment. The answer needs more than a glance at the falling share price.
Read my RaySearch review for what the report changes, and what it leaves intact.
The next decisions
My Pandora review is ready for a forthcoming issue. Demand is improving, but its move towards platinum-plated jewellery raises a different question. How much of the recovery will reach shareholders while the business pays for the transition? I have also been working through Ovzon’s defence contracts and the cost of adding satellite capacity.
The forthcoming November investment overview puts five cases side by side. Where would I put fresh capital? Which good businesses would I leave alone at today’s price? That comparison is the next step after reading the individual reports.
Beyond the existing coverage, I am investigating Medistim and Admicom. Both remain research candidates, with more work to do before an investment verdict.
Read the decision behind the headline
Become a paid Fjord Alpha member for the full Pexip and RaySearch reviews, including my valuations and verdicts. You will also receive the forthcoming November comparison.
Join by 30 November and save 20% on your annual subscription. Your discount continues on every annual renewal for as long as you remain subscribed.

